Newland Pharmaceutical Co., Ltd. announced that on July 21, 2026, it received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notification for amlodipine besylate API from the National Medical Products Administration. The registration number is Y20240001499, valid until July 20, 2031, and the status displayed on the CDE raw and auxiliary materials registration information platform is A. Amlodipine besylate is a long-acting calcium channel blocker used to treat hypertension, coronary heart disease, chronic stable angina, and vasospastic angina. The company stated that this approval will further enrich its product portfolio and enhance market competitiveness, while noting that pharmaceutical production and sales are subject to market conditions and other factors, involving a degree of uncertainty.
Henan Newland Pharmaceutical Co. Ltd. AReceived marketing approval for amlodipine besylate API from NMPA, enabling commercialization.